COATI

TITLE

Specific Antibiogram to guide Treatment for urinary tract Infections

DESCRIPTION
Baylor College of Medicine Creating an Outpatient-specific Antibiogram to guide Treatment for urinary tract Infections

NICU-AR

Subjects were in NICUs; the AR refers to ACCELERATE Repository

TITLE

Pediatrix Database Analysis – secondary analysis of ACCELERATE data set

DESCRIPTION
This was retrospective observational research with the objectives of describing the epidemiology of diseases in infants, conduct comparative effectiveness research and describe drug safety and efficacy.

January 2019

Our January 2019 newsletter provides highlights from ARLG at IDWeek 2018TM, held October 3rd-7th in San Francisco, CA. ARLG leaders, researchers, or committee members moderated panels and presented lectures, posters, or abstracts at close to 300 sessions.

In this issue, you can learn more about Sarah Doernberg, MD, MAS, of University of California, San Francisco who considers her role in the ARLG as a trialist in training. Dr. Doernberg has been involved in the development and execution of three protocols that each provide important contributions to the fight against antimicrobial resistance.

September 2018

link to September 2018 Newsletter PDFCheck out our September 2018 newsletter for our latest fact sheets and lay summaries of results for the RADICAL and PROOF studies.

In this issue, we interview Yohei Doi, MD, PhD, chair of the Gram-negative Committee who provides his thoughts and insights on contributions to date and
future plans for this committee.

This issue also spotlights Ephraim Tsalik, MD, PhD, and his role as the principal investigator for the Rapid Diagnostics in Categorizing Acute Lung Infections (RADICAL) study.

June 2018

The June 2018 newsletter features highlights from our Multi-Drug Resistance Organism (MDRO) global network meeting in Madrid, Spain, as well as an update from the ARLG Mentoring Program.

We also profile ARLG Research Fellow Judith Anesi, MD, and two Early Stage Investigator Grant recipients, Michael A. Liss, MD, MAS, FACS, and Jose M. Munita, MD. In addition to providing an update on their ARLG research, these award recipients discuss the impact of this funding to their careers and the benefits of the ARLG.

March 2018

Our March 2018 newsletter shares updates from the 2018 ARLG Operations Retreat, as well as highlights the ARLG Special Populations Special Emphasis Panel and the Pediatrics Subcommittee.

You can also learn more about Ritu Banerjee, MD, PhD, who along with other ARLG investigators developed the Rapid Identification and Susceptibility Testing for Gram-Negative Bacteremia, (RAPIDS-GN). This study is evaluating antimicrobial utilization, clinical outcomes, and healthcare costs among patients with Gram-negative blood system infections using a diagnostic platform that rapidly detects organisms
and phenotypic drug resistance.

CRACKLE

Consortium on Resistance against Carbapenems in Klebsiella Pneumoniae and other Enterobacteriaceae

An observational study that utilizes an existing CRKP consortium consisting of 20 hospitals that are part of 9 different health care systems. The primary objectives were:

1) To determine whether CRKP strain type is associated with outcomes in CRKP infections

2) To evaluate the constellation of clinical and microbiologic factors associated colistin and tigecycline non-suspectibility

3) To explore variation in treatment and outcomes of CRKP infections in various anatomical sites.